Article
Pharmacology & Pharmacy
Lekshmy Srinivas, Noble Gracious, Radhakrishnan R. Nair
Summary: Tacrolimus is an immunosuppressant used in solid organ transplantation. This study in South Indian renal transplant recipients investigated the effects of gene polymorphisms on tacrolimus concentrations and adverse effects. The findings suggest that genotype-guided initial dosing of tacrolimus can help achieve optimal drug levels and prevent adverse effects.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Health Care Sciences & Services
Remi Lenain, Mehdi Maanaoui, Aghiles Hamroun, Romain Larrue, Cynthia Van Der Hauwaert, Jean-Baptiste Gibier, Viviane Gnemmi, Sebastien Gomis, Myriam Labalette, Franck Broly, Benjamin Hennart, Nicolas Pottier, Marc Hazzan, Christelle Cauffiez, Francois Glowacki
Summary: The study found that implementing a tacrolimus capping strategy in CYP3A5*1/- recipients is associated with improved glomerular filtration rate without a significant increase in biopsy-proven acute rejection incidence.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Pharmacology & Pharmacy
Yilei Yang, Xin Huang, Yinping Shi, Rui Yang, Haiyan Shi, Xinmei Yang, Guoxiang Hao, Yi Zheng, Jianning Wang, Lequn Su, Yan Li, Wei Zhao
Summary: A CYP3A5 genotype-dependent drug-drug interaction was found between tacrolimus and nifedipine in Chinese renal transplant patients. Personalized therapy accounting for CYP3A5 genotype detection and therapeutic drug monitoring is necessary for these patients receiving tacrolimus and nifedipine treatment.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Xiang-Qian Gu, Dan Tang, Ping Wan, Tian Qin, Tai-Hua Yang, Ji Wu, Hao Ji, Jin-Chuan Liu, Feng Xue, Yuan-Jia Tang, Qiang Xia
Summary: The study shows that CYP3A5 gene polymorphism is the major factor influencing tacrolimus pharmacokinetics. Four miRNAs, including miR-29a-3p, miR-99a-5p, miR-532-5p, and miR-26b-5p, are identified as novel regulators of tacrolimus metabolism by affecting CYP3A5 expression through various mechanisms.
PHARMACOLOGICAL RESEARCH
(2021)
Article
Urology & Nephrology
Nuria Lloberas, Josep M. Grinyo, Helena Colom, Anna Vidal-Alabro, Pere Fontova, Raul Rigo-Bonnin, Ariadna Padro, Oriol Bestard, Edoardo Melilli, Nuria Montero, Ana Coloma, Anna Manonelles, Maria Meneghini, Alex Fava, Joan Torras, Josep M. Cruzado
Summary: This study developed and validated a population pharmacokinetic model for tacrolimus dosing, which was found to be superior to traditional labeling-based dosing in achieving therapeutic targets. The model showed faster attainment of therapeutic levels and reduced dosage adjustments compared to the standard approach.
KIDNEY INTERNATIONAL
(2023)
Article
Pharmacology & Pharmacy
Marith I. Francke, Louise M. Andrews, Hoang Lan Le, Jacqueline van de Wetering, Marian C. Clahsen-van Groningen, Teun van Gelder, Ron H. N. van Schaik, Bronno van der Holt, Brenda C. M. de Winter, Dennis A. Hesselink
Summary: Algorithm-based tacrolimus dosing leads to the achievement of the target tacrolimus C-0 in as many as 58% of patients on day 3 after kidney transplantation.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Pharmacology & Pharmacy
Paola Krall, Dominique Yanez, Angelica Rojo, Angela Delucchi, Miguel Cordova, Jorge Morales, Pia Boza, Alonso de la Rivera, Natalie Espinoza, Natalia Armijo, Luis E. Castaneda, Mauricio J. Farfan, Carolina Salas
Summary: The study indicated that genotyping CYP3A5 and UGT1A9 genes might be useful in guiding dosing and monitoring of TAC and MPA in pediatric kidney transplant recipients. Different genotypes of these genes can influence drug concentration and dose requirements in patients.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Benedetta C. Sallustio, Benjamin D. Noll, Rong Hu, Daniel T. Barratt, Jonathan Tuke, Janet K. Coller, Graeme R. Russ, Andrew A. Somogyi
Summary: Recipient and donor CYP3A5 and ABCB1 3435C>T genotypes do not determine allograft tacrolimus exposure in kidney transplant recipients. However, tacrolimus dose and C-0Blood are significant predictors of C-Graft, and the relationship between C-0Blood and C-Graft appears to differ in the presence or absence of acute nephrotoxicity.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Zhe Guo, Qi Chen, Juan Liu, Shan Li, He Wang, Rui Tang, Zhenyu Zhang
Summary: Platelet counts declined significantly after DDLT, especially on postoperative day 3, and continued at low levels for a week thereafter in all groups. Tacrolimus nadir levels were significantly higher in GG/GG genotype patients compared to A*/A* genotype patients, leading to a higher incidence of hemorrhage. Risk of thrombocytopenia after DDLT on postoperative day 3 was increased with a combination of specific tacrolimus blood concentration and spleen size.
Article
Health Care Sciences & Services
Pablo Zubiaur, Maria Dolores Benedicto, Gonzalo Villapalos-Garcia, Marcos Navares-Gomez, Gina Mejia-Abril, Manuel Roman, Samuel Martin-Vilchez, Dolores Ochoa, Francisco Abad-Santos
Summary: The study demonstrated the impact of SLCO1B1 phenotype and other genetic variants on atorvastatin pharmacokinetics, suggesting dose adjustments based on SLCO1B1 and revealing interesting findings related to CYP3A5 genotype.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Review
Pharmacology & Pharmacy
Hui Yang, Yiqi Sun, Xiaojia Yu, Xiaopeng Hu, Wei Wang, Xiaodong Zhang, Lihong Liu
Summary: The study found that in kidney transplantation patients, genotype-guided tacrolimus dosing led to more patients having therapeutic tacrolimus concentrations in the targeted range and achieving therapeutic levels faster compared to conventional dosing. However, there were no statistical differences in clinical endpoints including delayed graft function, acute rejection, graft survival, and adverse effects between the two groups. The study suggested that pharmacogenetics based on CYP3A5 genotype did not provide utility in optimizing tacrolimus dosing.
CLINICAL PHARMACOKINETICS
(2021)
Article
Pharmacology & Pharmacy
Amy L. Pasternak, Vincent D. Marshall, Christina L. Gersch, James M. Rae, Michael Englesbe, Jeong M. Park
Summary: The CYP3A5 genotype may predict healthcare resource utilization in heart transplant recipients, but not in renal transplant recipients. Other factors like age and induction therapy were associated with higher total charges. Future studies should investigate the impact of genotype-guided dosing strategies for tacrolimus on healthcare resource utilization.
PHARMACOGENOMICS & PERSONALIZED MEDICINE
(2021)
Article
Medicine, Research & Experimental
Stefania Cheli, Marta Fusi, Annalisa De Silvestri, Igor Bonini, Emilio Clementi, Dario Cattaneo, Cristina Montrasio, Sara Baldelli
Summary: The study indicates that CYP3A5 gene polymorphisms may significantly impact the metabolism of linezolid, increasing the risk of underexposure in patients, while P-glycoprotein gene polymorphisms seem to have no role.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Article
Medical Laboratory Technology
Marith Francke, Dennis A. Hesselink, Louise M. Andrews, Teun van Gelder, Ron J. Keizer, Brenda C. M. de Winter
Summary: The combination of model-based follow-up dosing with algorithm-based initial tacrolimus dose has the potential to minimize under- and overexposure to tacrolimus in the early posttransplant phase, although the additional effect of model-based follow-up dosing on initial algorithm-based dosing seems small.
THERAPEUTIC DRUG MONITORING
(2022)
Article
Immunology
Justa Friebus-Kardash, Ejona Nela, Birte Mohlendick, Andreas Kribben, Winfried Siffert, Falko Markus Heinemann, Ute Eisenberger
Summary: The CYP3A5 genotype can affect the metabolism and clearance rate of tacrolimus, which may have an impact on alloimmunization and allograft function. Patients who are CYP3A5 expressers have lower tacrolimus trough levels despite requiring higher dosages, and they are more prone to developing de novo DSAs and antibody-mediated rejection.